[Inhibiting E7 oncogene in CaSki cells of cervical cancer by vector-based RNA interference technique]

Area of Science:

• Molecular Biology
• Virology
• Cancer Research

Context:

• Cervical cancer is a significant global health concern, often driven by persistent infections with high-risk human papillomavirus (HPV) types.
• The HPV oncoprotein E7 is crucial for the development and progression of HPV-associated cervical cancers.
• Targeting viral oncogenes like HPV16E7 presents a potential therapeutic strategy.

Purpose:

• To evaluate the efficacy of vector-based RNA interference (RNAi) in suppressing the expression of the HPV16E7 gene.
• To assess the inhibitory effects of specific small interfering RNA (siRNA) expression vectors on HPV16E7 in CaSki cervical cancer cells.

Summary:

• HPV16E7-specific siRNA expression vectors (P1, P2, P3) were constructed and delivered into CaSki cells using liposomes.
• Real-time RT-PCR and Western blot analysis confirmed a reduction in HPV16E7 mRNA and protein levels post-transfection.
• Vector P1 demonstrated the most potent inhibition, achieving 92.86% and 81.0% reduction in HPV16E7 mRNA and protein, respectively, three weeks after transfection.

Impact:

• This study validates the potential of siRNA-based RNAi as a method to inhibit HPV16E7 gene expression in cervical cancer cells.
• The findings suggest that targeted inhibition of HPV oncogenes via RNAi could be a viable therapeutic approach for cervical cancer.
• Further research into optimizing vector delivery and efficacy could pave the way for novel anti-HPV therapies.